BerGenBio ASA

As of December 31, 2024, BerGenBio ASA has 609,941.00 shares outstanding.

These figures are as of December 31, 2024. The price-to-sales ratio is 1,845.65, and the price-to-book ratio stands at -2.49.

These figures are as of December 31, 2024. The EV/Sales ratio of 1,699.56 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative.

As of December 31, 2024, BerGenBio ASA maintains a current ratio of 2.46, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 6.88, indicating elevated leverage, while an interest coverage ratio of -32.18 demonstrates limited ability to service its debt obligations.

Over the twelve months ended December 31, 2024, BerGenBio ASA posted a negative return on equity (ROE) of -465.89, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -80.66, reflecting losses generated across the asset base.

As of the close on March 23, 2026, BerGenBio ASA's stock has declined approximately 61.16% over the past 52 weeks. The 50-day moving average sits at 97.09, while the 200-day moving average is 176.89.

Over the twelve months ended December 31, 2024, BerGenBio ASA posted a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -17,833.73 and net profit margin of -16,424.65 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2024. Free cash flow yield is negative at -9.79: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -8.28, meaning BerGenBio ASA raised more capital through share issuance and new debt than it returned via dividends and buybacks.

BerGenBio ASA's most recent stock split took place on January 20, 2026 with a 100:1 split ratio.

As of December 31, 2024, BerGenBio ASA has an Altman Z-Score of 7.45, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.